

Rewriting treatment

for people
with cancer
and other serious
diseases through
epigenetic
medicines




The company was founded on November 1, 2007 and is headquartered in Cambridge, Massachusetts.



190+ employees
fully committed to helping
patients with cancer
and other serious diseases



Shared purpose
Inspired
Passionate
Motivated
Sense of urgency



Epizyme has a rich history of epigenetic innovation and research partnerships

>10 candidate-quality compounds identified

4 new chemical entities in clinical development

Discovered multiple first-in-class molecules



Investigational agents lack regulatory approval required for commercialization and patient use.

*RNA and DNA helicase.

CRISPR, clustered regularly interspaced short palindromic repeats; HAT, histone acetyltransferase; HMT, histone methyltransferase; HMTi, histone methyltransferase inhibitor; NDA, New Drug Application; RMTi, arginine methyltransferase inhibitor.

www.epizyme.com

400 Technology Square, Cambridge, MA 02139

(617) 229-5872

© 2020 Epizyme, Inc. All Rights Reserved

CO-ES-CP-20-0001